Resources from the same session
LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
Presenter: Fabrice André
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
Presenter: Binghe Xu
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA18 and LBA19
Presenter: Sung-Bae Kim
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Slides
Webcast
LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
Presenter: Matthew Goetz
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
211MO - Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
Presenter: Miguel Martin Jimenez
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
212MO - AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
Presenter: Sara Tolaney
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
213MO - Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
Presenter: Monica Arnedos
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
Presenter: Frederik Marmé
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
215MO - ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer
Presenter: Jon Amund Kyte
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
Presenter: Elisabetta Munzone
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast